About this trial
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.
Eligibility criteria
Qualifiers
patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse;
patients with confirmed symptomatic MM;
ability to understand and voluntarily sign written informed consent;
ability to comply with study procedures;
Disqualifiers
pregnancy or lactation;
inability to comprehend study procedures or cooperate with protocol requirements;
any other condition judged by the investigator to potentially interfere with study participation.
Trial design
Treatments tested in this trial
- 68Ga-BCMA PET/CT
Treatment groups
Sponsors and collaborators
Peking University First Hospital
Lead sponsor
The First Hospital of Jilin University
Collaborator
The Second Hospital of Hebei Medical University
Collaborator
Beijing Anzhen Hospital
Collaborator
Beijing Tsinghua Changgeng Hospital
Collaborator